Arcturus Therapeutics Holdings Inc. (ARCT)
- Previous Close
11.24 - Open
11.24 - Bid 10.91 x 100
- Ask 11.00 x 100
- Day's Range
10.81 - 11.72 - 52 Week Range
8.04 - 45.00 - Volume
388,476 - Avg. Volume
427,706 - Market Cap (intraday)
296.962M - Beta (5Y Monthly) 2.37
- PE Ratio (TTM)
-- - EPS (TTM)
-3.00 - Earnings Date May 12, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
70.30
Arcturus Therapeutics Holdings Inc. engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms includes LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate that is in phase 2 clinical trial for cystic fibrosis. Its product pipeline includes KOSTAIVE for the treatment of covid 19; ARCT-2138 (LUNAR-FLU), which is in phase 1 clinical trial for the treatment of seasonal influenza; ARCT-2304 (LUNAR-H5N1) that is in phase 1 clinical trial for the treatment of Pandemic Influenza; ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3 clinical trial; and ARCT-2303 for monovalent that is in Phase 3 clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
arcturusrx.comRecent News: ARCT
View MorePerformance Overview: ARCT
Trailing total returns as of 5/7/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ARCT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ARCT
View MoreValuation Measures
Market Cap
296.96M
Enterprise Value
88.48M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.14
Price/Book (mrq)
1.23
Enterprise Value/Revenue
0.64
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-53.14%
Return on Assets (ttm)
-15.46%
Return on Equity (ttm)
-31.16%
Revenue (ttm)
152.31M
Net Income Avi to Common (ttm)
-80.94M
Diluted EPS (ttm)
-3.00
Balance Sheet and Cash Flow
Total Cash (mrq)
237.03M
Total Debt/Equity (mrq)
11.85%
Levered Free Cash Flow (ttm)
-9.02M